Sanofi Targets Real-World Teplizumab Data in Type 1 Diabetes: What Investors Should Watch
TipRanks (Thu, 12-Mar 12:33 PM ET)
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries
TipRanks (Thu, 12-Mar 12:32 PM ET)
Sanofi Wins Japan Orphan Status for Rilzabrutinib and Moves to Strengthen Governance
TipRanks (Tue, 10-Mar 10:57 AM ET)
FDA vaccine chief to leave the agency again
Seeking Alpha News (Sat, 7-Mar 7:41 AM ET)
Sanofi announces leadership evolution in Specialty Care Business Unit
PRNewswire (Tue, 17-Feb 8:30 AM ET)
Business Wire (Mon, 29-Dec 6:37 PM ET)
Market Chameleon (Mon, 15-Dec 3:16 AM ET)
Business Wire (Mon, 15-Dec 8:05 AM ET)
Sanofi’s $470M Vigil Neuroscience Deal Underscores 2025’s Record Year for Biotech Innovation
Market Chameleon (Tue, 18-Nov 2:10 AM ET)
Bullish On SNY? You Might Want To Consider This Credit Put Spread Expiring in 18 Days
Market Chameleon (Tue, 27-Aug 8:30 AM ET)
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sanofi - American Depositary Shares trades on the NASDAQ stock market under the symbol SNY.
As of March 12, 2026, SNY stock price declined to $43.63 with 3,555,331 million shares trading.
SNY has a beta of 0.74, meaning it tends to be less sensitive to market movements. SNY has a correlation of 0.18 to the broad based SPY ETF.
SNY has a market cap of $105.38 billion. This is considered a Large Cap stock.
Last quarter Sanofi - American Depositary Shares reported $13 billion in Revenue and $.89 earnings per share. This fell short of revenue expectation by $-251 million and exceeded earnings estimates by $.05.
In the last 3 years, SNY traded as high as $60.12 and as low as $42.63.
The top ETF exchange traded funds that SNY belongs to (by Net Assets): PVAL, PPH, FVD, AVDE, PID.
SNY has underperformed the market in the last year with a price return of -22.0% while the SPY ETF gained +21.1%. SNY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.7% and -8.3%, respectively, while the SPY returned -3.1% and -3.9%, respectively.
SNY support price is $43.18 and resistance is $44.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNY shares will trade within this expected range on the day.